|
WO2008027558A2
(en)
|
2006-08-31 |
2008-03-06 |
Codon Devices, Inc. |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
|
CN103502448B
(zh)
|
2010-11-12 |
2017-03-29 |
Gen9股份有限公司 |
核酸合成的方法和设备
|
|
EP2637780B1
(en)
|
2010-11-12 |
2022-02-09 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
|
US11560585B2
(en)
|
2011-01-31 |
2023-01-24 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
|
JP6069224B2
(ja)
|
2011-01-31 |
2017-02-01 |
アプライズ バイオ， インコーポレイテッド |
細胞において複数のエピトープを同定する方法
|
|
MX2013010911A
(es)
|
2011-03-23 |
2015-03-03 |
Pioneer Hi Bred Int |
Metodos para producir un locus de rasgo transgenico complejo.
|
|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
LT2944693T
(lt)
|
2011-08-26 |
2019-08-26 |
Gen9, Inc. |
Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
|
|
WO2013055995A2
(en)
|
2011-10-14 |
2013-04-18 |
President And Fellows Of Harvard College |
Sequencing by structure assembly
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US9637739B2
(en)
*
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
|
CN111876409A
(zh)
|
2012-04-24 |
2020-11-03 |
Gen9股份有限公司 |
在体外克隆中分选核酸和多重制备物的方法
|
|
IN2014DN09261A
(https=)
|
2012-04-25 |
2015-07-10 |
Regeneron Pharma |
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
EP2861737B1
(en)
|
2012-06-19 |
2019-04-17 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
|
AU2013280661A1
(en)
|
2012-06-25 |
2015-01-22 |
Gen9, Inc. |
Methods for nucleic acid assembly and high throughput sequencing
|
|
EP4357457B1
(en)
|
2012-10-23 |
2024-10-16 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
EP3363902B1
(en)
*
|
2012-12-06 |
2019-11-27 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
WO2014093718A1
(en)
*
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
DK2931897T3
(en)
|
2012-12-12 |
2018-02-05 |
Broad Inst Inc |
CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
CA2894684A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
CN105121648B
(zh)
|
2012-12-12 |
2021-05-07 |
布罗德研究所有限公司 |
用于序列操纵的系统、方法和优化的指导组合物的工程化
|
|
CA2895155C
(en)
|
2012-12-17 |
2021-07-06 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
|
EP3919505B1
(en)
|
2013-01-16 |
2023-08-30 |
Emory University |
Uses of cas9-nucleic acid complexes
|
|
MX2015010841A
(es)
|
2013-02-20 |
2016-05-09 |
Regeneron Pharma |
Modificacion genetica de ratas.
|
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
MX374090B
(es)
|
2013-03-14 |
2025-03-05 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
AU2014227653B2
(en)
|
2013-03-15 |
2017-04-20 |
The General Hospital Corporation |
Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
|
|
US20140273235A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Regents Of The University Of Minnesota |
ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
|
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
SI2986729T1
(sl)
|
2013-04-16 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Ciljana sprememba genoma podgane
|
|
CN105683376A
(zh)
*
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
US11414695B2
(en)
|
2013-05-29 |
2022-08-16 |
Agilent Technologies, Inc. |
Nucleic acid enrichment using Cas9
|
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
EP4596565A3
(en)
|
2013-06-04 |
2025-11-05 |
President And Fellows Of Harvard College |
Rna-guided transcriptional regulation
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
MX2015017312A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
|
|
EP3011030B1
(en)
|
2013-06-17 |
2023-11-08 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
|
|
WO2015006294A2
(en)
*
|
2013-07-10 |
2015-01-15 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
CA3109801C
(en)
|
2013-08-22 |
2024-01-09 |
Andrew Cigan |
Plant genome modification using guide rna/cas endonuclease systems and methods of use
|
|
US9925248B2
(en)
|
2013-08-29 |
2018-03-27 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for RNA-guided treatment of HIV infection
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
EP3418379B1
(en)
|
2013-09-18 |
2020-12-09 |
Kymab Limited |
Methods, cells & organisms
|
|
CN105899665B
(zh)
*
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
US9546384B2
(en)
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
|
SMT201800653T1
(it)
|
2013-12-11 |
2019-01-11 |
Regeneron Pharma |
Metodi e composizioni per la modificazione indirizzata a bersaglio di un genoma
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
BR112016013207A2
(pt)
|
2013-12-12 |
2017-09-26 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
MX2016007325A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
|
|
AU2014361834B2
(en)
|
2013-12-12 |
2020-10-22 |
Massachusetts Institute Of Technology |
CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
EP4063503A1
(en)
|
2014-02-11 |
2022-09-28 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
|
US12460231B2
(en)
|
2014-04-02 |
2025-11-04 |
Editas Medicine, Inc. |
Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
|
|
US11439712B2
(en)
|
2014-04-08 |
2022-09-13 |
North Carolina State University |
Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes
|
|
WO2015168125A1
(en)
|
2014-04-28 |
2015-11-05 |
Recombinetics, Inc. |
Multiplex gene editing in swine
|
|
EP3149171A1
(en)
|
2014-05-30 |
2017-04-05 |
The Board of Trustees of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
|
RS60359B1
(sr)
|
2014-06-06 |
2020-07-31 |
Regeneron Pharma |
Postupci i kompozicije za modifikovanje ciljanog lokusa
|
|
HUE049405T2
(hu)
|
2014-06-23 |
2020-09-28 |
Regeneron Pharma |
Nukleáz-közvetített DNS-összeállítás
|
|
KR102386101B1
(ko)
|
2014-06-26 |
2022-04-14 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
|
|
WO2016007839A1
(en)
|
2014-07-11 |
2016-01-14 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
AU2015288157A1
(en)
|
2014-07-11 |
2017-01-19 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
ES3047792T3
(en)
|
2014-07-14 |
2025-12-04 |
Univ California |
Crispr/cas transcriptional modulation
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
EP3183358B1
(en)
|
2014-08-19 |
2020-10-07 |
President and Fellows of Harvard College |
Rna-guided systems for probing and mapping of nucleic acids
|
|
ES2730378T3
(es)
*
|
2014-08-27 |
2019-11-11 |
Caribou Biosciences Inc |
Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9
|
|
EP3633032A3
(en)
|
2014-08-28 |
2020-07-29 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
|
WO2016040594A1
(en)
*
|
2014-09-10 |
2016-03-17 |
The Regents Of The University Of California |
Reconstruction of ancestral cells by enzymatic recording
|
|
CN108064129A
(zh)
|
2014-09-12 |
2018-05-22 |
纳幕尔杜邦公司 |
玉米和大豆中复合性状基因座的位点特异性整合位点的产生和使用方法
|
|
WO2016057951A2
(en)
*
|
2014-10-09 |
2016-04-14 |
Life Technologies Corporation |
Crispr oligonucleotides and gene editing
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
DK3207124T3
(da)
|
2014-10-15 |
2019-08-12 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
|
|
US10612042B2
(en)
|
2014-10-24 |
2020-04-07 |
Avectas Limited |
Delivery across cell plasma membranes
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US20170306306A1
(en)
*
|
2014-10-24 |
2017-10-26 |
Life Technologies Corporation |
Compositions and Methods for Enhancing Homologous Recombination
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
ES2731437T3
(es)
|
2014-11-21 |
2019-11-15 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
|
|
CN105695485B
(zh)
*
|
2014-11-27 |
2020-02-21 |
中国科学院上海生命科学研究院 |
一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用
|
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016100857A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
|
JP2017537645A
(ja)
*
|
2014-12-19 |
2017-12-21 |
アプライズ バイオ， インコーポレイテッド |
細胞の選択された部分集団中の複数エピトープを識別するための方法
|
|
KR102530821B1
(ko)
|
2014-12-19 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
|
|
WO2016106244A1
(en)
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
US11248240B2
(en)
*
|
2015-01-29 |
2022-02-15 |
Meiogenix |
Method for inducing targeted meiotic recombinations
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
US11046952B2
(en)
*
|
2015-03-16 |
2021-06-29 |
The Broad Institute, Inc. |
Encoding of DNA vector identity via iterative hybridization detection of a barcode transcript
|
|
BR112017017260A2
(pt)
|
2015-03-27 |
2018-04-17 |
Du Pont |
construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
|
|
EP3280803B1
(en)
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
CA2982966C
(en)
|
2015-04-24 |
2024-02-20 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
|
EP3294879A4
(en)
*
|
2015-05-14 |
2019-02-20 |
University of Southern California |
OPTIMIZED GENETIZATION WITH A RECOMBINANT ENDONUCLEASE SYSTEM
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
KR20220139447A
(ko)
|
2015-05-29 |
2022-10-14 |
노쓰 캐롤라이나 스테이트 유니버시티 |
크리스퍼 핵산을 사용하여 박테리아, 고세균, 조류 및 효모를 스크리닝하는 방법
|
|
US20160346360A1
(en)
|
2015-05-29 |
2016-12-01 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
|
EA037359B1
(ru)
|
2015-06-01 |
2021-03-17 |
Тэмпл Юниверсити - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
|
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
KR102468240B1
(ko)
|
2015-06-15 |
2022-11-17 |
노쓰 캐롤라이나 스테이트 유니버시티 |
핵산 및 rna-기반 항미생물제를 효율적으로 전달하기 위한 방법 및 조성물
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
TWI813532B
(zh)
|
2015-06-18 |
2023-09-01 |
美商博得學院股份有限公司 |
降低脱靶效應的ｃｒｉｓｐｒ酶突變
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
EP4545544A3
(en)
|
2015-06-29 |
2025-10-08 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
|
US11479793B2
(en)
|
2015-07-15 |
2022-10-25 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
AU2016316845B2
(en)
|
2015-08-28 |
2022-03-10 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017040511A1
(en)
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
|
WO2017040786A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Massachusetts Institute Of Technology |
Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
|
|
WO2017049129A2
(en)
*
|
2015-09-18 |
2017-03-23 |
President And Fellows Of Harvard College |
Methods of making guide rna
|
|
US20180237800A1
(en)
*
|
2015-09-21 |
2018-08-23 |
The Regents Of The University Of California |
Compositions and methods for target nucleic acid modification
|
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
EP4491732A3
(en)
*
|
2015-10-08 |
2025-03-26 |
President and Fellows of Harvard College |
Multiplexed genome editing
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
US11111508B2
(en)
|
2015-10-30 |
2021-09-07 |
Brandeis University |
Modified CAS9 compositions and methods of use
|
|
JP6882282B2
(ja)
|
2015-11-03 |
2021-06-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
三次元核酸含有マトリックスの立体撮像のための方法と装置
|
|
BR112018009515A2
(pt)
|
2015-11-11 |
2018-11-06 |
Univ Minnesota |
sistema e métodos de biocontenção/biocontrole
|
|
CN106893739A
(zh)
|
2015-11-17 |
2017-06-27 |
香港中文大学 |
用于靶向基因操作的新方法和系统
|
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
|
EA201891317A3
(ru)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
|
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
|
WO2017115128A2
(en)
|
2015-12-30 |
2017-07-06 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
WO2017123559A2
(en)
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
|
ES2875747T3
(es)
|
2016-01-11 |
2021-11-11 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia
|
|
CN105624187A
(zh)
*
|
2016-02-17 |
2016-06-01 |
天津大学 |
酿酒酵母基因组定点突变的方法
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
WO2017151444A1
(en)
|
2016-02-29 |
2017-09-08 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
|
|
WO2017161043A1
(en)
|
2016-03-16 |
2017-09-21 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
EP3433362B1
(en)
*
|
2016-03-23 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
CN110382692A
(zh)
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN109415761B
(zh)
|
2016-04-25 |
2022-09-20 |
哈佛学院董事及会员团体 |
用于原位分子检测的杂交链反应方法
|
|
WO2017188797A1
(ko)
*
|
2016-04-28 |
2017-11-02 |
연세대학교 산학협력단 |
In vivo에서 rna-가이드 뉴클레아제의 활성을 고처리량 방식으로 평가하는 방법
|
|
IL323024A
(en)
|
2016-05-20 |
2025-10-01 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide RNAs
|
|
US12043856B2
(en)
*
|
2016-05-24 |
2024-07-23 |
The Translational Genomics Research Institute |
Molecular tagging methods and sequencing libraries
|
|
LT3604527T
(lt)
|
2016-06-02 |
2021-06-25 |
Sigma-Aldrich Co., Llc |
Programuojamų, dnr surišančių baltymų panaudojimas tiksliniam genomo modifikavimui pagerinti
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
US10017760B2
(en)
|
2016-06-24 |
2018-07-10 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CN115252807A
(zh)
*
|
2016-07-27 |
2022-11-01 |
利兰斯坦福初级大学董事会 |
用于核酸递送的解体型细胞穿透性复合物
|
|
CN109563505A
(zh)
|
2016-07-28 |
2019-04-02 |
帝斯曼知识产权资产管理有限公司 |
用于真核细胞的组装系统
|
|
JP2019523009A
(ja)
|
2016-07-29 |
2019-08-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
|
|
WO2018026976A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CN109923216B
(zh)
|
2016-08-31 |
2024-08-02 |
哈佛学院董事及会员团体 |
将生物分子的检测组合到使用荧光原位测序的单个试验的方法
|
|
WO2018049009A2
(en)
*
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
|
WO2018064208A1
(en)
|
2016-09-28 |
2018-04-05 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
CA3038960A1
(en)
|
2016-09-30 |
2018-04-05 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
AU2017341926B2
(en)
|
2016-10-14 |
2022-06-30 |
The General Hospital Corporation |
Epigenetically regulated site-specific nucleases
|
|
EP3526320A1
(en)
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
WO2018093797A1
(en)
|
2016-11-15 |
2018-05-24 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
|
CN110582301A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和蛋白质有效负载递送的方法和组合物
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
CA3047904A1
(en)
|
2016-12-22 |
2018-06-28 |
Avectas Limited |
Vector-free intracellular delivery to non-adherent cells by reversible permeabilization
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
WO2018129129A1
(en)
|
2017-01-05 |
2018-07-12 |
Rutgers, The State University Of New Jersey |
Targeted gene editing platform independent of dna double strand break and uses thereof
|
|
EP3565907B1
(en)
|
2017-01-06 |
2022-05-04 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
IL314915B1
(en)
|
2017-01-23 |
2026-02-01 |
Regeneron Pharma |
Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
EP3580212A4
(en)
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US12331319B2
(en)
|
2017-04-12 |
2025-06-17 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
|
US11913015B2
(en)
|
2017-04-17 |
2024-02-27 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
|
WO2018195402A1
(en)
|
2017-04-20 |
2018-10-25 |
Egenesis, Inc. |
Methods for generating genetically modified animals
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11834665B2
(en)
|
2017-05-10 |
2023-12-05 |
Regents Of The University Of Minnesota |
Programmable transcription factors and methods
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
US20200172895A1
(en)
|
2017-05-25 |
2020-06-04 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
|
KR20200026878A
(ko)
|
2017-06-06 |
2020-03-11 |
지머젠 인코포레이티드 |
균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼
|
|
KR20200026874A
(ko)
|
2017-06-06 |
2020-03-11 |
지머젠 인코포레이티드 |
대장균 개량을 위한 htp 게놈 공학 플랫폼
|
|
CN111065736A
(zh)
*
|
2017-06-07 |
2020-04-24 |
国立大学法人东京大学 |
针对颗粒状角膜变性症的基因治疗药物
|
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
BR112019027086A2
(pt)
|
2017-06-21 |
2020-07-07 |
Timothy A. Bertram |
células renais bioativas imunoprivilegiadas para o tratamento de doença renal
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
CN111182790A
(zh)
|
2017-07-31 |
2020-05-19 |
瑞泽恩制药公司 |
Crispr报告体非人类动物及其用途
|
|
CN110891419A
(zh)
|
2017-07-31 |
2020-03-17 |
瑞泽恩制药公司 |
评价crispr/cas-诱导的与外源供体核酸的体内重组
|
|
WO2019028032A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
AR113154A1
(es)
|
2017-09-29 |
2020-01-29 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para edición del genoma
|
|
MX394999B
(es)
|
2017-09-29 |
2025-03-24 |
Regeneron Pharma |
Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
|
|
EP3688161A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
|
PT3688162T
(pt)
|
2017-09-29 |
2024-04-23 |
Intellia Therapeutics Inc |
Formulações
|
|
BR112020006256A2
(pt)
|
2017-09-29 |
2020-10-20 |
Intellia Therapeutics, Inc. |
método in vitro de administração de mrna usando nanopartículas de lipídio
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
|
WO2019099560A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
CA3086620A1
(en)
|
2018-01-12 |
2019-07-18 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
|
WO2019144061A1
(en)
|
2018-01-19 |
2019-07-25 |
Duke University |
Genome engineering with crispr-cas systems in eukaryotes
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
KR20200124702A
(ko)
|
2018-02-23 |
2020-11-03 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
신규한 cas9 오르소로그
|
|
WO2019178426A1
(en)
|
2018-03-14 |
2019-09-19 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CN111885915B
(zh)
|
2018-03-19 |
2023-04-28 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
JP7555822B2
(ja)
|
2018-04-19 |
2024-09-25 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
ゲノム編集のための組成物および方法
|
|
CN121555430A
(zh)
|
2018-05-11 |
2026-02-24 |
比姆医疗股份有限公司 |
使用可编程碱基编辑器系统取代病原性氨基酸的方法
|
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
WO2019229722A1
(en)
|
2018-06-01 |
2019-12-05 |
Avectas Limited |
Cell engineering platform
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
|
CN113348245A
(zh)
|
2018-07-31 |
2021-09-03 |
博德研究所 |
新型crispr酶和系统
|
|
BR112021001546A2
(pt)
|
2018-07-31 |
2021-05-04 |
Intellia Therapeutics, Inc. |
composições e métodos para a edição de gene do hidroxiácido oxidase 1 (hao1) para o tratamento da hiperoxalúria primária tipo 1 (ph1)
|
|
WO2020037490A1
(en)
*
|
2018-08-21 |
2020-02-27 |
Institute Of Hematology And Blood Diseases Hospital, Cams & Pumc |
Method of genome editing in mammalian stem cell
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
BR112021005718A2
(pt)
|
2018-09-28 |
2021-06-22 |
Intellia Therapeutics, Inc. |
composições e métodos para edição de genes de lactato desidrogenase (ldha)
|
|
WO2020072250A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
|
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
WO2020072253A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system and uses thereof for screening for variant cells
|
|
US12264330B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
JP2022512703A
(ja)
|
2018-10-16 |
2022-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のための組成物および方法
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
EP3874037A4
(en)
|
2018-10-31 |
2021-12-15 |
Zymergen, Inc. |
DETERMINIST MULTIPLEXED SET OF DNA LIBRARIES
|
|
EP3874048A1
(en)
*
|
2018-11-01 |
2021-09-08 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
CA3117730A1
(en)
|
2018-11-09 |
2020-05-14 |
Inari Agriculture, Inc. |
Rna-guided nucleases and dna binding proteins
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
US12365888B2
(en)
|
2018-12-14 |
2025-07-22 |
Pioneer Hi-Bred International, Inc. |
CRISPR-Cas systems for genome editing
|
|
CA3120799A1
(en)
|
2018-12-20 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
US12460230B2
(en)
|
2019-02-10 |
2025-11-04 |
The J. David Gladstone Institutes |
Modified mitochondrion and methods of use thereof
|
|
CA3130789A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
CN113728106A
(zh)
|
2019-03-08 |
2021-11-30 |
齐默尔根公司 |
微生物中的迭代基因组编辑
|
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
|
EP3768826B1
(en)
|
2019-03-18 |
2023-12-13 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
|
CA3127814C
(en)
|
2019-03-18 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
BR112021019224A2
(pt)
|
2019-03-28 |
2021-11-30 |
Intellia Therapeutics Inc |
Polinucleotídeos, composições e métodos para expressão de polipeptídeo
|
|
AU2020248337A1
(en)
|
2019-03-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
|
|
EP3946598A1
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
WO2020206162A1
(en)
|
2019-04-03 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
|
ES2966625T3
(es)
|
2019-04-04 |
2024-04-23 |
Regeneron Pharma |
Roedores que comprenden un locus del factor de coagulación 12 humanizado
|
|
WO2020206134A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
US11622547B2
(en)
|
2019-06-07 |
2023-04-11 |
Regeneran Pharmaceuticals, Inc. |
Genetically modified mouse that expresses human albumin
|
|
US11845957B2
(en)
|
2019-06-14 |
2023-12-19 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
|
BR112022003505A2
(pt)
|
2019-08-27 |
2022-05-24 |
Vertex Pharma |
Composições e métodos para tratamento de distúrbios associados a dna repetitivo
|
|
CN114616002A
(zh)
|
2019-09-13 |
2022-06-10 |
瑞泽恩制药公司 |
使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
|
|
CN115175996A
(zh)
|
2019-09-20 |
2022-10-11 |
博德研究所 |
新颖vi型crispr酶和系统
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
CN114945671A
(zh)
*
|
2019-11-01 |
2022-08-26 |
上海蓝十字医学科学研究所 |
靶向性修饰植物基因组序列的方法
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
EP4064830A1
(en)
|
2019-11-29 |
2022-10-05 |
Basf Se |
Increasing resistance against fungal infections in plants
|
|
JP7793519B2
(ja)
|
2019-12-19 |
2026-01-05 |
ビーエーエスエフ ソシエタス・ヨーロピア |
ファインケミカルを生成する際の空時収率、炭素変換効率、及び炭素基質適応性の増加
|
|
KR20220119408A
(ko)
|
2019-12-20 |
2022-08-29 |
바스프 에스이 |
터펜의 독성 감소 및 미생물에서 생산 잠재성 증가
|
|
US11060141B1
(en)
|
2019-12-23 |
2021-07-13 |
Stilla Technologies |
Multiplex drop-off digital polymerase chain reaction methods
|
|
WO2021155063A1
(en)
|
2020-01-29 |
2021-08-05 |
Readcoor, Llc |
Compositions and methods for analyte detection
|
|
JP2023512758A
(ja)
*
|
2020-02-07 |
2023-03-29 |
インテリア セラピューティクス，インコーポレイテッド |
カリクレイン（ｋｌｋｂ１）遺伝子編集のための組成物および方法
|
|
CN115485385A
(zh)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
用于使肿瘤细胞对免疫疗法敏感的方法和组合物
|
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
US20210290757A1
(en)
|
2020-03-23 |
2021-09-23 |
Avectas Limited |
Engineering of dendritic cells for generation of vaccines against sars-cov-2
|
|
WO2021202938A1
(en)
|
2020-04-03 |
2021-10-07 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
|
CN115427566A
(zh)
|
2020-04-08 |
2022-12-02 |
阿斯利康(瑞典)有限公司 |
用于改善的位点特异性修饰的组合物和方法
|
|
KR20230017783A
(ko)
|
2020-04-28 |
2023-02-06 |
인텔리아 테라퓨틱스, 인크. |
시험관내 세포 전달 방법
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
EP4179079A1
(en)
|
2020-07-10 |
2023-05-17 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
US20220096606A1
(en)
|
2020-09-09 |
2022-03-31 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
|
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
|
CA3191387A1
(en)
|
2020-09-30 |
2022-04-07 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
|
EP4232583A1
(en)
|
2020-10-21 |
2023-08-30 |
Massachusetts Institute of Technology |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
|
EP4240854A1
(en)
|
2020-11-06 |
2023-09-13 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
|
US20240002839A1
(en)
|
2020-12-02 |
2024-01-04 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
CA3204997A1
(en)
|
2020-12-11 |
2022-06-16 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing mhc class ii in a cell
|
|
TW202242101A
(zh)
|
2020-12-23 |
2022-11-01 |
美商英特利亞醫療公司 |
用於細胞中基因修飾ciita之組合物及方法
|
|
AU2021409732A1
(en)
|
2020-12-23 |
2023-07-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
CN117203319A
(zh)
|
2021-02-01 |
2023-12-08 |
阿维塔斯有限公司 |
递送平台
|
|
EP4288548A4
(en)
*
|
2021-02-05 |
2025-01-15 |
Dharmacon, Inc. |
FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION
|
|
JP2024505672A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのナチュラルキラー細胞受容体２ｂ４組成物及び方法
|
|
WO2022170194A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
|
JP2024506016A
(ja)
|
2021-02-08 |
2024-02-08 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのｔ細胞免疫グロブリン及びムチンドメイン３（ｔｉｍ３）組成物及び方法
|
|
EP4298221A1
(en)
|
2021-02-26 |
2024-01-03 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
|
TW202302848A
(zh)
|
2021-02-26 |
2023-01-16 |
美商維泰克斯製藥公司 |
以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
|
|
JP7695687B2
(ja)
*
|
2021-03-23 |
2025-06-19 |
国立研究開発法人農業・食品産業技術総合研究機構 |
ジャスモン酸類を用いた蒸散抑制剤
|
|
CA3210702A1
(en)
*
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Gene transfer vectors and methods of engineering cells
|
|
JP2024513087A
(ja)
|
2021-04-07 |
2024-03-21 |
アストラゼネカ・アクチエボラーグ |
部位特異的改変のための組成物及び方法
|
|
BR112023021477A2
(pt)
|
2021-04-17 |
2024-01-30 |
Intellia Therapeutics Inc |
Composições de nanopartículas lipídicas
|
|
US20240200106A1
(en)
|
2021-04-17 |
2024-06-20 |
Intellia Thrapeutics, Inc. |
Lipid nanoparticles compositions
|
|
CR20230535A
(es)
|
2021-04-17 |
2024-02-16 |
Intellia Therapeutics Inc |
Inhibidores de proteína cinasa dependiente de adn y composiciones y usos de estos
|
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
|
WO2022240846A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
KR20240027676A
(ko)
|
2021-06-02 |
2024-03-04 |
라이엘 이뮤노파마, 인크. |
Nr4a3-결핍 면역 세포 및 이의 용도
|
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
|
EP4392060A1
(en)
|
2021-08-24 |
2024-07-03 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
|
EP4399302A2
(en)
|
2021-09-08 |
2024-07-17 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
US20240336896A1
(en)
|
2021-10-14 |
2024-10-10 |
Lonza Sales Ag |
Modified producer cells for extracellular vesicle production
|
|
AU2022366987A1
(en)
|
2021-10-14 |
2024-05-16 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
KR20240099393A
(ko)
|
2021-11-01 |
2024-06-28 |
톰 바이오사이언시스, 인코포레이티드 |
유전자 편집 기구와 핵산 카고의 동시 전달을 위한 단일 작제물 플랫폼
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
EP4426822A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
EP4426338A2
(en)
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
CN118632622A
(zh)
|
2021-12-08 |
2024-09-10 |
瑞泽恩制药公司 |
突变型肌纤蛋白疾病模型及其用途
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
|
KR20240128067A
(ko)
|
2021-12-29 |
2024-08-23 |
브리스톨-마이어스 스큅 컴퍼니 |
랜딩 패드 세포주의 생성
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
EP4473103A2
(en)
|
2022-02-02 |
2024-12-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
|
EP4490291A1
(en)
|
2022-03-08 |
2025-01-15 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
US20250302998A1
(en)
|
2022-05-09 |
2025-10-02 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
KR20250027283A
(ko)
|
2022-05-19 |
2025-02-25 |
라이엘 이뮤노파마, 인크. |
nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
CN119421951A
(zh)
|
2022-05-31 |
2025-02-11 |
瑞泽恩制药公司 |
用于c9orf72重复序列扩增疾病的crispr干扰疗法
|
|
EP4558634A1
(en)
|
2022-07-18 |
2025-05-28 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
|
JP2025525569A
(ja)
|
2022-07-18 |
2025-08-05 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
遺伝子編集成分、システム、及び使用方法
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
IL318625A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
|
|
IL318553A
(en)
|
2022-08-05 |
2025-03-01 |
Regeneron Pharma |
Aggregation-resistant TDP-43 variants
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
|
CN120265314A
(zh)
|
2022-09-28 |
2025-07-04 |
瑞泽恩制药公司 |
抗体抗性修饰受体以增强基于细胞的疗法
|
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
|
IL320016A
(en)
|
2022-11-04 |
2025-06-01 |
Regeneron Pharma |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024137766A2
(en)
|
2022-12-21 |
2024-06-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
EP4654982A1
(en)
|
2023-01-27 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Modified rhabdovirus glycoproteins and uses thereof
|
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
|
EP4677067A1
(en)
|
2023-03-07 |
2026-01-14 |
Intellia Therapeutics, Inc. |
Cish compositions and methods for immunotherapy
|
|
CN121127605A
(zh)
|
2023-03-29 |
2025-12-12 |
阿斯利康(瑞典)有限公司 |
使用抑制剂来提高CRISPR/Cas插入的效率
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
IL324634A
(en)
|
2023-05-15 |
2026-01-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
TW202502729A
(zh)
|
2023-05-19 |
2025-01-16 |
美商英特利亞醫療公司 |
可電離胺脂質
|
|
CN121568725A
(zh)
|
2023-06-15 |
2026-02-24 |
里珍纳龙药品有限公司 |
用于听力病症的基因疗法
|
|
AU2024309884A1
(en)
|
2023-06-30 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
AU2024315073A1
(en)
|
2023-07-28 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
AU2024317483A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
CN121605117A
(zh)
|
2023-08-01 |
2026-03-03 |
巴斯夫植物科学有限公司 |
通过表达msbp1蛋白增加抗性
|
|
WO2025027165A1
(en)
|
2023-08-01 |
2025-02-06 |
Basf Plant Science Company Gmbh |
Increased resistance by expression of an ics protein
|
|
AU2024324870A1
(en)
|
2023-08-14 |
2026-02-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
TW202515994A
(zh)
|
2023-08-14 |
2025-04-16 |
美商英特利亞醫療公司 |
用於對ｃｄ７０進行基因修飾之組合物及方法
|
|
TW202521564A
(zh)
|
2023-08-14 |
2025-06-01 |
美商英特利亞醫療公司 |
用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025078978A1
(en)
|
2023-10-09 |
2025-04-17 |
Avectas Limited |
Transfection of cells via reversible permeabilization
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025111340A1
(en)
*
|
2023-11-20 |
2025-05-30 |
William Marsh Rice University |
Engineered extrachromosomal nucleic acids and methods of use thereof
|
|
WO2025149983A2
(en)
|
2024-01-12 |
2025-07-17 |
Avectas Limited |
Delivery platform with integrated non-viral transfection and cell processing
|
|
WO2025149984A2
(en)
|
2024-01-12 |
2025-07-17 |
Avectas Limited |
Delivery platform with flow-through system (fts)
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025162985A1
(en)
|
2024-01-30 |
2025-08-07 |
Basf Plant Science Company Gmbh |
Increased plant disease resistance by expression of a glycine-rich protein
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025202473A1
(en)
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
WO2025217398A1
(en)
|
2024-04-10 |
2025-10-16 |
Lyell Immunopharma, Inc. |
Methods for culturing cells with improved culture medium
|
|
EP4677108A1
(en)
|
2024-04-22 |
2026-01-14 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
WO2025259669A1
(en)
|
2024-06-10 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for characterizing modified oligonucleotides
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|
|
WO2026064425A2
(en)
|
2024-09-17 |
2026-03-26 |
Dxome Co., Ltd. |
Mirror image crispr-cas compositions
|
|
WO2026072529A1
(en)
|
2024-09-24 |
2026-04-02 |
University Of Florida Research Foundation, Incorporated |
Mettl7a for improved embryo competence
|
|
WO2026080515A2
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cells and cell lines and methods of use thereof
|